目的 探索高压氧联合丁苯肽及艾地苯醌治疗血管性痴呆患者的疗效及对氧化应激、认知功能的影响。 方法 前瞻性选取2016年6月至2021年6月衡水市人民医院全科医学科收治的300例血管性痴呆患者，根据治疗方法分为对照组和观察组，每组150例。对照组患者采用丁苯肽及艾地苯醌治疗，观察组患者采用高压氧联合丁苯肽、艾地苯醌治疗。治疗3个月后，比较2组患者的血清超氧化物歧化酶（SOD）、丙二醛（MDA）、过氧化脂质（LPO）水平和疾病缓解率。比较2组患者治疗前后的简易精神状态（MMSE）量表评分。比较2组患者治疗期间转氨酶轻度升高、头晕、皮疹、胃肠道反应等不良反应发生情况。 结果 治疗后，观察组患者血清SOD、MDA、LPO的改善情况优于对照组，差异有统计学意义（P<0.001）。观察组患者治疗4、8、12周后的疾病缓解率均高于对照组，差异有统计学意义（P<0.01）。与治疗前比较，2组患者治疗后的MMSE评分均升高，且观察组高于对照组，差异有统计学意义（P<0.001）。2组患者的不良反应发生率比较差异无统计学意义（P>0.05）。 结论 高压氧联合丁苯肽、艾地苯醌治疗血管性痴呆，可改善氧化应激，提高患者的认知功能。 Objective To explore the efficacy of hyperbaric oxygen（HBO）therapy combined with butylbenzene peptide and idebenone on vascular dementia and its effects on oxidative stress and cognitive function. Methods A total of 300 patients with vascular dementia admitted to the Department of General Medicine of Harrison International Peace Hospital from June 2016 to June 2021 were prospectively selected and divided into control group and observation group，with 150 cases in each group. The patients in the control group received treatment with butylbenzene peptide and idebenone，while the patients in the observation group received HBO therapy combined with butylbenzene peptide and idebenone. After three months of treatment，the serum levels of superoxide dismutase（SOD），malondialdehyde（MDA），and lipid peroxidation（LPO）as well as the disease remission rate were compared between the two groups. The Mini-Mental State Examination（MMSE）scores of the patients before and after treatment were compared. The occurrence of adverse reactions，such as mild elevation of aminopherase，dizziness，rash，and gastrointestinal reactions during the treatment period，were compared between the two groups. Results After treatment，the serum levels of SOD，MDA，and LPO were significantly improved in the observation group than those in the control group（P<0.001）. The disease remission rates in the observation group after 4 weeks，8 weeks，and 12 weeks of treatment were significantly higher than those in the control group（P<0.01）. Compared with before treatment，the MMSE score of both groups increased after treatment，and the score of the observation group was higher than that in the control group，all the differences were statistically significant（P<0.001）. There was no significant difference in the incidence of adverse reactions between the two groups（P>0.05）. Conclusion HBO therapy combined with butylbenzene and idebenone can improve oxidative stress and enhance cognitive function in patients with vascular dementia.
Therapeutic effect of hyperbaric oxygen combined with butylbenzene peptide and idebenone on vascular dementia and its effects on oxidative stress and cognitive function
Objective To explore the efficacy of hyperbaric oxygen（HBO）therapy combined with butylbenzene peptide and idebenone on vascular dementia and its effects on oxidative stress and cognitive function. Methods A total of 300 patients with vascular dementia admitted to the Department of General Medicine of Harrison International Peace Hospital from June 2016 to June 2021 were prospectively selected and divided into control group and observation group，with 150 cases in each group. The patients in the control group received treatment with butylbenzene peptide and idebenone，while the patients in the observation group received HBO therapy combined with butylbenzene peptide and idebenone. After three months of treatment，the serum levels of superoxide dismutase（SOD），malondialdehyde（MDA），and lipid peroxidation（LPO）as well as the disease remission rate were compared between the two groups. The Mini-Mental State Examination（MMSE）scores of the patients before and after treatment were compared. The occurrence of adverse reactions，such as mild elevation of aminopherase，dizziness，rash，and gastrointestinal reactions during the treatment period，were compared between the two groups. Results After treatment，the serum levels of SOD，MDA，and LPO were significantly improved in the observation group than those in the control group（P<0.001）. The disease remission rates in the observation group after 4 weeks，8 weeks，and 12 weeks of treatment were significantly higher than those in the control group（P<0.01）. Compared with before treatment，the MMSE score of both groups increased after treatment，and the score of the observation group was higher than that in the control group，all the differences were statistically significant（P<0.001）. There was no significant difference in the incidence of adverse reactions between the two groups（P>0.05）. Conclusion HBO therapy combined with butylbenzene and idebenone can improve oxidative stress and enhance cognitive function in patients with vascular dementia.
Hyperbaric oxygenButylbenzeneIdebenoneVascular dementiaOxidative stressCognitive function
万方数据
